Drug-Eluting Balloon Catheters - Global Strategic Business Report

The global market for Drug-Eluting Balloon Catheters was estimated at US$618.8 Million in 2024 and is projected to reach US$935.9 Million by 2030, growing at a CAGR of 7.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Drug-Eluting Balloon Catheters market.

Global 'Drug-Eluting Balloon Catheters' Market - Key Trends & Drivers Summarized

Why Are Drug-Eluting Balloon Catheters a Preferred Choice for Vascular Interventions?

The rise in cardiovascular diseases (CVDs) and peripheral artery diseases (PADs) has significantly increased the demand for drug-eluting balloon (DEB) catheters, which offer a less invasive and highly effective alternative to traditional stents. These catheters deliver antiproliferative drugs, such as paclitaxel and sirolimus, directly to the affected arteries, reducing restenosis and minimizing the need for repeat procedures. Unlike drug-eluting stents (DES), which leave behind a permanent implant, DEBs provide a transient yet effective therapeutic solution, ensuring vessel patency without long-term complications like late thrombosis. This makes them particularly beneficial for patients with high risks of bleeding, small vessel disease, or those undergoing repeat interventions. Additionally, the growing preference for minimally invasive procedures, especially among aging populations, has driven the increased adoption of DEB catheters in coronary, peripheral, and arteriovenous fistula (AVF) treatments.

What Innovations Are Enhancing the Effectiveness of Drug-Eluting Balloon Catheters?

Breakthroughs in polymer-free drug coatings, prolonged drug retention strategies, and targeted drug delivery mechanisms are driving improvements in DEB technology. Next-generation hydrophilic carriers, nano-based drug formulations, and bioabsorbable materials have significantly enhanced drug adhesion to arterial walls, ensuring sustained therapeutic effects. Advancements in balloon design and catheter flexibility have also improved the precision and safety of drug delivery, minimizing procedural risks and optimizing outcomes. Furthermore, real-time imaging technologies, including intravascular ultrasound (IVUS) and optical coherence tomography (OCT), are now being integrated into DEB systems, allowing for enhanced visualization and placement accuracy. As regulatory bodies such as the FDA and European Medicines Agency (EMA) approve more indication-specific DEBs, the market is witnessing a surge in clinical trials evaluating their efficacy in diabetic vascular complications, below-the-knee interventions, and dialysis access maintenance.

How Are Regulatory Mandates and Market Trends Driving Adoption?

The increasing regulatory approvals for DEBs across multiple vascular indications have accelerated their global adoption. In Europe, drug-eluting balloon catheters have already gained widespread acceptance as a first-line treatment for in-stent restenosis, while regulatory agencies in the U.S. and Asia-Pacific are expanding approvals for coronary, peripheral, and even neurovascular applications. Hospitals and ambulatory surgical centers are shifting towards catheter-based interventions due to their cost-effectiveness and shorter hospital stays, further fueling demand. Additionally, government initiatives promoting value-based healthcare and outpatient angioplasty procedures have provided a strong push toward DEB utilization. The growing emphasis on hybrid procedures that combine DEBs with bioresorbable scaffolds is also a key market trend, offering better long-term vascular healing outcomes.

What Are the Primary Market Growth Drivers?

The growth in the Drug-Eluting Balloon Catheter market is driven by the increasing burden of cardiovascular and peripheral artery diseases, advancements in drug delivery nanotechnology, and the rising adoption of minimally invasive endovascular procedures. The expansion of DEB applications beyond coronary interventions, particularly in treating diabetic foot ulcers, critical limb ischemia, and hemodialysis access failures, has created new market opportunities. Additionally, rising healthcare expenditures, increasing investments in interventional cardiology, and the shift toward outpatient angioplasty centers are supporting market expansion. With ongoing technological advancements and continuous clinical validation, DEB catheters are poised to become an indispensable component of next-generation vascular care.

Report Scope

The report analyzes the Drug-Eluting Balloon Catheters market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Material (Polyurethane, Nylon, Others); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Catheterization Laboratories)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Polyurethane segment, which is expected to reach US$532.7 Million by 2030 with a CAGR of a 6.1%. The Nylon segment is also set to grow at 8.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $168.6 Million in 2024, and China, forecasted to grow at an impressive 11.0% CAGR to reach $194.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Drug-Eluting Balloon Catheters Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Drug-Eluting Balloon Catheters Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Drug-Eluting Balloon Catheters Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Aachen Resonance GmbH, Aesculap (B. Braun SE), Balton Sp. z o.o., Bayer AG, Becton, Dickinson and Company (BD) and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 42 Featured):

• Aachen Resonance GmbH
• Aesculap (B. Braun SE)
• Balton Sp. z o.o.
• Bayer AG
• Becton, Dickinson and Company (BD)
• Biosensors International
• Biotronik AG
• Boston Scientific Corporation
• Cardionovum GmbH
• Concept Medical
• Convatec Group
• Cordis (Cardinal Health)
• Districlass Médical
• Eurocor GmbH
• eucatech AG
• iVascular S.L.U.
• Jiangsu Changmei Medtech Co., Ltd.
• Koninklijke Philips N.V.
• Laborie Medical Technologies
• Lepu Medical Technology (Beijing) Co., Ltd.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry